Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
DTP Vaccines Market: By Type, By End-user, By Age Group, and Geography
DTP Vaccines Market: By Type, By End-user, By Age Group, and Geography
DTP Vaccines Market size was valued at US$ 7,319.8 million in 2023 and is projected to grow at 6.7% CAGR over the forecast years to reach US$ 11,525.2 million by 2030. The DTP (Diphtheria, Tetanus, and Pertussis) vaccines market encompasses the production, distribution, and sale of combination vaccines that protect against these three bacterial infections. These vaccines are cornerstone components of childhood immunization programs worldwide. The market growth can be attributed to various factors, including increasing awareness about vaccine-preventable diseases, growing government initiatives for immunization, rising birth rates in developing countries, and ongoing research and development in vaccine technology.
According to the World Health Organization (WHO), global DTP3 immunization coverage reached 84% of infants in 2022, with approximately 110 million infants receiving the vaccine. However, in 2022, 14.3 million infants did not receive an initial dose of the DTP vaccine, pointing to a lack of access to immunization and other health services, and an additional 6.2 million are partially vaccinated. Of the 20.5 million, just under 60% of these children live in 10 countries: Angola, Brazil, the Democratic Republic of the Congo, Ethiopia, India, Indonesia, Mozambique, Nigeria, Pakistan and the Philippines, highlighting the potential for market expansion. The growth of the market will be challenged by factors such as vaccine hesitancy in some populations, with a 2019 study published in The Lancet reporting that 79% of people worldwide agreed that vaccines are safe, but this rate varied significantly between countries.
Study Period
2024-2030Base Year
2023CAGR
6.7%Largest Market
Asia PacificFastest Growing Market
North America
The increasing focus on preventive healthcare and the rising incidence of pertussis cases in some regions are driving the demand for DTP vaccines. The Centers for Disease Control and Prevention (CDC) reported 18,617 pertussis cases in the United States in 2019, with an incidence rate of 4.7 per 100,000 population. Globally, the WHO estimated 132,754 pertussis cases in 2019, emphasizing the ongoing need for effective vaccination programs. Governments and international health organizations are also pushing for higher vaccination coverage, particularly in developing countries. The Gavi Vaccine Alliance has supported the immunization of over 888 million children with pentavalent vaccines (which include DTP components) since 2000. Technological advancements in vaccine development, such as the creation of acellular pertussis vaccines with improved safety profiles, are also contributing to market expansion. However, the market faces challenges such as the complexity of manufacturing combination vaccines and the need for continuous cold chain management, with the WHO estimating that up to 50% of vaccines are wasted globally every year, largely due to failures in the cold chain.
The global DTP Vaccines Market is segmented into North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. North America and Europe currently dominate the market due to well-established healthcare infrastructure and strong government support for immunization programs. In the United States, the CDC reports that 94% of children aged 19-35 months received 3 or more doses of DTP vaccines in 2019. However, the Asia-Pacific region is expected to witness the highest growth rate. In India, under the Universal Immunization Programme, DTP3 coverage increased from 72% in 2015-16 to 91% in 2019-20, according to the National Family Health Survey. China reported over 99% coverage for DTP3 in 2019, as per WHO data. The Middle East & Africa region is also expected to see substantial growth, with countries like Saudi Arabia achieving over 95% DTP3 coverage in 2019.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2024-2030 |
|
Market Size in 2023 |
US$ 7,319.8 million |
|
Market Size in 2030 |
US$ 11,525.2 million |
|
Market CAGR |
6.7% |
|
By Type |
|
|
By End User |
|
|
By Age Group |
|
|
By Region |
|
Download Free Sample Report
The global DTP vaccines market was valued at US$ 7,319.8 million in 2023 and is projected to grow at 6.7% CAGR over the forecast years to reach US$ 11,525.2 million by 2030.
The global DTP vaccines market is segmented based on type, end-user, age group and geography.
The leading players are Sanofi Pasteur, GSK, Merck & Co., Inc., Pfizer Inc., Serum Institute of India, Panacea Biotec, and Biological E Limited.
North America currently holds the largest share, followed closely by Europe.
Key drivers include increasing awareness about vaccine-preventable diseases, growing government initiatives for immunization, rising birth rates in developing countries, and ongoing R&D in vaccine technology. The WHO's goal to achieve 90% global coverage for DTP3 by 2030 is also a significant factor.
| 1.Executive Summary |
| 2.Global DTP Vaccines Market Introduction |
| 2.1.Global DTP Vaccines Market - Taxonomy |
| 2.2.Global DTP Vaccines Market - Definitions |
| 2.2.1.Type |
| 2.2.2.End User |
| 2.2.3.Age Group |
| 2.2.4.Region |
| 3.Global DTP Vaccines Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global DTP Vaccines Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global DTP Vaccines Market By Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 5.1. DTaP (Diphtheria, Tetanus, acellular Pertussis) |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Tdap (Tetanus, diphtheria, acellular pertussis) |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Others (DT, Td, etc.) |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 6.Global DTP Vaccines Market By End User, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 6.1. Hospitals |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Clinics |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Vaccination Centers |
| 6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 7.Global DTP Vaccines Market By Age Group, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 7.1. Adults |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Pediatrics |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 8.Global DTP Vaccines Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia Pacific (APAC) |
| 8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Middle East and Africa (MEA) |
| 8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Latin America |
| 8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 9.North America DTP Vaccines Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 9.1. Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.DTaP (Diphtheria, Tetanus, acellular Pertussis) |
| 9.1.2.Tdap (Tetanus, diphtheria, acellular pertussis) |
| 9.1.3.Others (DT, Td, etc.) |
| 9.2. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Hospitals |
| 9.2.2.Clinics |
| 9.2.3.Vaccination Centers |
| 9.3. Age Group Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Adults |
| 9.3.2.Pediatrics |
| 9.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.4.1.United States of America (USA) |
| 9.4.2.Canada |
| 10.Europe DTP Vaccines Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 10.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.DTaP (Diphtheria, Tetanus, acellular Pertussis) |
| 10.1.2.Tdap (Tetanus, diphtheria, acellular pertussis) |
| 10.1.3.Others (DT, Td, etc.) |
| 10.2. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Hospitals |
| 10.2.2.Clinics |
| 10.2.3.Vaccination Centers |
| 10.3. Age Group Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Adults |
| 10.3.2.Pediatrics |
| 10.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Germany |
| 10.4.2.France |
| 10.4.3.Italy |
| 10.4.4.United Kingdom (UK) |
| 10.4.5.Spain |
| 11.Asia Pacific (APAC) DTP Vaccines Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 11.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.DTaP (Diphtheria, Tetanus, acellular Pertussis) |
| 11.1.2.Tdap (Tetanus, diphtheria, acellular pertussis) |
| 11.1.3.Others (DT, Td, etc.) |
| 11.2. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Hospitals |
| 11.2.2.Clinics |
| 11.2.3.Vaccination Centers |
| 11.3. Age Group Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Adults |
| 11.3.2.Pediatrics |
| 11.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.China |
| 11.4.2.India |
| 11.4.3.Australia and New Zealand (ANZ) |
| 11.4.4.Japan |
| 11.4.5.Rest of APAC |
| 12.Middle East and Africa (MEA) DTP Vaccines Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 12.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.DTaP (Diphtheria, Tetanus, acellular Pertussis) |
| 12.1.2.Tdap (Tetanus, diphtheria, acellular pertussis) |
| 12.1.3.Others (DT, Td, etc.) |
| 12.2. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Hospitals |
| 12.2.2.Clinics |
| 12.2.3.Vaccination Centers |
| 12.3. Age Group Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Adults |
| 12.3.2.Pediatrics |
| 12.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.GCC Countries |
| 12.4.2.South Africa |
| 12.4.3.Rest of MEA |
| 13.Latin America DTP Vaccines Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 13.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.DTaP (Diphtheria, Tetanus, acellular Pertussis) |
| 13.1.2.Tdap (Tetanus, diphtheria, acellular pertussis) |
| 13.1.3.Others (DT, Td, etc.) |
| 13.2. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Hospitals |
| 13.2.2.Clinics |
| 13.2.3.Vaccination Centers |
| 13.3. Age Group Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Adults |
| 13.3.2.Pediatrics |
| 13.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Brazil |
| 13.4.2.Mexico |
| 13.4.3.Rest of LA |
| 14. Competition Landscape |
| 14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 14.2.1.Sanofi Pasteur |
| 14.2.2.GSK (GlaxoSmithKline) |
| 14.2.3.Merck & Co., Inc. |
| 14.2.4.Pfizer Inc. |
| 14.2.5.Serum Institute of India |
| 14.2.6.Panacea Biotec |
| 14.2.7.Biological E Limited |
| 15. Research Methodology |
| 16. Appendix and Abbreviations |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.